A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell Carcinoma

Imiquimod 5% Cream for the Treatment of Periocular Basal Cell Carcinoma

NCT00803907 ·Status: UNKNOWN ·Phase: PHASE4

Efficacy and Safety Trial of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma

NCT01808950 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

A Pilot Study of the Treatment of Facial Nodular and Nodulocystic Basal Cell Carcinoma With Double Curettage and Cautery Followed by Application of Imiquimod to the Base

NCT00463359 ·Status: UNKNOWN ·Phase: NA

Treatment of Primary Basal Cell Carcinomas of the Skin With Combination of Topical Imiquimod and Cryosurgery

NCT01212562 ·Status: COMPLETED

Investigating the Effect of Topical Imiquimod on Sebaceous Hyperplasia

NCT06840470 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4

Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1

NCT00865644 ·Status: COMPLETED ·Phase: PHASE1

Safety and Efficacy of Imiquimod Applied in Dose-Cycle for Actinic Keratoses

NCT00175643 ·Status: COMPLETED ·Phase: PHASE3

Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts

NCT00189293 ·Status: COMPLETED ·Phase: PHASE4

Randomized Clinical Trial Evaluating the Efficacy of Topical Imiquimod in High Grade Cervical Intraepithelial Lesions

NCT03233412 ·Status: COMPLETED ·Phase: PHASE2

Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma

NCT02301494 ·Status: WITHDRAWN ·Phase: NA

Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses

NCT00774787 ·Status: COMPLETED ·Phase: PHASE4

Topical Imiquimod in Treating Patients With Recurrent Paget's Disease of the Vulva

NCT00504023 ·Status: COMPLETED ·Phase: NA

Topical Challenge With Omiganan and Imiquimod in Healthy Volunteers

NCT03071679 ·Status: COMPLETED ·Phase: PHASE1

Topical Imiquimod Treatment of Oral Dysplasia

NCT07210775 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Double-blind, Randomized, Single Centre, Vehicle-controlled Study to Evaluate the Safety and Tolerability of a New Topical Formulation Containing 0,09% Imiquimod (Limtop) in Healthy Subjects

NCT01567683 ·Status: COMPLETED ·Phase: PHASE1

1-Year Follow up to the 1473-IMIQ Study

NCT00114023 ·Status: COMPLETED

Betaglucin 0.2% Versus Imiquimod 5% in Treatment of Ano-genital Warts: Combined Results From Triple Blind Controlled Study

NCT03901690 ·Status: UNKNOWN ·Phase: PHASE3

Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL)

NCT01676831 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults

NCT00115141 ·Status: COMPLETED ·Phase: PHASE2

Follow-up Study to Evaluate Sustained Clearance Rates of Actinic Keratoses up to One Year

NCT00668733 ·Status: COMPLETED

Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults

NCT00114920 ·Status: COMPLETED ·Phase: PHASE2

Imiquimod 5% Cream in the Treatment of External Genital or Perianal Warts in HIV+ Patients

NCT00761371 ·Status: COMPLETED ·Phase: PHASE4

Study With a Topical Gel to Treat Common Warts in Adults

NCT00117871 ·Status: COMPLETED ·Phase: PHASE2

Primary Imiquimod Treatment Versus Surgery for Vulvar Intraepithelial Neoplasia

NCT01861535 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of a New Topical Formulation With Imiquimod (Limtop) Applied 1, 3 or 7 Times Weekly During 2 x 2 Weeks Treatment for Actinic Keratosis on the Head

NCT01611480 ·Status: COMPLETED ·Phase: PHASE2